IS

Intuitive Surgical, Inc.

ISRGHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$10.06B
+20.5% YoY
Net Income
$2.86B
+23.0% YoY
EBITDA
$3.62B
+27.2% YoY

Scan Results

Daily timeframe
9 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 1CONFIRMED MACD Positive CrossoverHistogram +0.3184, positive momentum
RSI OversoldRSI 27.7, below 30, stock may be oversold
Jun 30 MACD Positive CrossoverHistogram +0.5553, positive momentum
About Intuitive Surgical, Inc.

Headquartered within the healthcare sector, Intuitive Surgical, Inc. focuses on Medical Instruments & Supplies services and products. Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. With a market capitalization of $122.33B, it sits in large-cap territory. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung.

Key stats
Market Cap$122.33B
P/E (TTM)39.57
Fwd P/E28.83
EPS$8.73
52W Change-33.4%
ROE17.4%
Analysis

Intuitive Surgical, Inc. reports $8.63B in cash and $0 in total debt. Return on equity stands at 17.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has grown from $6.22B (2022) to $10.06B (2025), reflecting a 62% increase over the period.

As with any equity investment, ISRG carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing ISRG's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms